Covishield is a version of an AstraZeneca shot. The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added as quoted by Reuters.
Dr Amitav Banerjee - an epidemiologist who leads DY Patil Medical College in Pune has earlier said that Covishield carried a ‘double whammy of risk’.
He noted that its use had been discouraged in most European countries due to blood clots. "It also carries the risk of myocarditis.
There is accumulating evidence that this heart condition is associated with the mRNA vaccines. Many would perhaps not know that Covishield carries a DNA gene on an adenovirus which after injection gets converted into mRNA in the body," he said.